Current Issues in Molecular Biology,
Год журнала:
2024,
Номер
46(5), С. 4768 - 4786
Опубликована: Май 15, 2024
The
emergence
of
combination
antiretroviral
therapy
(cART)
has
greatly
transformed
the
life
expectancy
people
living
with
HIV
(PWH).
Today,
over
76%
individuals
have
access
to
this
life-saving
therapy.
However,
progress
come
a
new
challenge:
an
increase
in
age-related
non-AIDS
conditions
among
patients
HIV.
These
manifest
earlier
PWH
than
uninfected
individuals,
accelerating
aging
process.
Like
PWH,
population
experiences
immunosenescence
marked
by
increased
proinflammatory
environment.
This
phenomenon
is
linked
chronic
inflammation,
driven
part
cellular
structures
called
inflammasomes.
Inflammatory
signaling
pathways
activated
HIV-1
infection
play
key
role
inflammasome
formation,
suggesting
crucial
link
between
and
inflammatory
state.
review
outlines
processes
triggered
aging,
focus
on
also
explores
current
research
regarding
inflammasomes
potential
strategies
for
targeting
mitigate
inflammation.
Further
presents
unique
opportunity
develop
targeted
interventions
innovative
therapeutic
modalities
combating
aging-associated
processes.
Gut Microbes Reports,
Год журнала:
2025,
Номер
unknown, С. 1 - 20
Опубликована: Янв. 15, 2025
Autoimmune
thyroid
diseases
(AITDs)
are
the
most
common
organ-specific
autoimmune
disorders
characterized
by
dysfunction
and
immune
system
deficiencies.
In
recent
decades,
role
of
microbiome
in
has
gained
increasing
attention,
with
emerging
research
linking
gut
alterations
to
development
AITDs.
This
review
summarizes
current
knowledge
on
relationship
between
AITDs
microbiome.
Additionally,
it
emphasizes
oral
AITDs,
an
area
often
overlooked
research.
Beyond
microbiome,
virome
mycobiome
have
been
recognized
as
critical
but
underexplored
components
human
potentially
contributing
dysregulation
pathogenesis
The
also
explores
modulating
for
managing
including
diet
adjustment,
potential
use
probiotics,
postbiotics,
symbiotics,
even
fecal
microbiota
transplantation
(FMT)
restore
a
balanced
that
may
positively
influence
and,
extension,
course
thoroughly
intricate
gut,
microbiomes,
paving
way
precision
medicine
applications
Examining
microbiota-thyroid
interactions
highlights
targeted,
personalized
treatments
novel
therapeutic
therapies,
guiding
future
strategies
more
effective
precisely
tailored
AITD
management
approaches.
EMBO Molecular Medicine,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 16, 2025
Abstract
The
gut
microbiome,
or
the
community
of
microorganisms
residing
in
gastrointestinal
tract,
has
emerged
as
an
important
factor
breast
cancer
etiology
and
treatment.
Specifically,
impact
bacterial
populations
on
therapeutic
outcomes
is
emerging
area
research.
microbiota’s
role
modifying
pharmacokinetics
chemotherapy
endocrine-targeting
therapies
can
alter
drug
efficacy
toxicity
profiles.
In
addition,
microbiome’s
capacity
to
regulate
systemic
inflammation
immune
responses
may
influence
effectiveness
both
conventional
immunotherapeutic
strategies
for
treatment
cancer.
Overall,
while
bidirectional
interactions
between
microbiome
are
still
being
studied,
its
increasingly
recognized.
Future
research
provide
more
definitive
insights
help
develop
personalized
harness
improve
outcomes.
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(5), С. 2028 - 2028
Опубликована: Фев. 26, 2025
The
human
immune
system
is
closely
linked
to
microbiota
such
as
a
complex
symbiotic
relationship
during
the
coevolution
of
vertebrates
and
microorganisms.
transfer
microorganisms
from
mother's
newborn
begins
before
birth
gestation
considered
initial
phase
intestinal
(IM).
gut
an
important
site
where
can
establish
colonies.
IM
contains
polymicrobial
communities,
which
show
interactions
with
diet
host
immunity.
tendency
towards
dysbiosis
influenced
by
local
but
also
extra-intestinal
factors
inflammatory
processes,
infections,
or
septic
state
that
aggravate
it.
Pathogens
could
trigger
response,
proinflammatory
responses.
In
addition,
changes
in
influence
community
structure
additional
translocation
pathogenic
non-pathogenic
bacteria.
Finally,
inflammation
has
been
found
be
factor
growth
microorganisms,
particularly
its
role
sepsis.
aim
this
article
able
detect
current
knowledge
mechanisms
lead
cause
bacterial
risk
infection
vice
versa.
Fermentation,
Год журнала:
2025,
Номер
11(4), С. 186 - 186
Опубликована: Апрель 1, 2025
Saccharomyces
cerevisiae
var.
boulardii
is
a
probiotic
yeast
widely
recognized
for
its
ability
to
enhance
gut
health
and
modulate
host’s
microbiome.
However,
there
are
limited
data
on
large-scale
cultivation
in
stirred
tank
bioreactors
subsequent
downstream
processing
into
functional
product.
Different
recipe
formulations
were
evaluated
the
with
highest
biomass
yield
lowest
process
time
was
selected.
Once
optimised
batch
validated
replicate
batches,
statistical
analysis
indicated
high
level
of
reproducibility,
low
variability
across
key
performance
indicators
such
as
concentration
(unit),
CFU
production
(CFU.mL−1),
substrate
utilization
efficiency
(g.g−1).
The
mean
growth
age
bioreactor
25.33
±
1.16
h,
CV
4.56%,
indicating
minimal
deviation
between
batches.
Similarly,
final
viable
exhibited
1.46
×
108
CFU.mL−1
11.68%,
remaining
within
an
acceptable
range
biological
processes,
while
had
(CV
3.94%)
95%
CI
12.134–13.266
g.L−1,
highlighting
accuracy
consistency
process.
Productivity
indicators,
including
cell
productivity
(growth
time—biomass)
YPP
(biomass),
maintained
values
(3.933%
3.389%,
respectively),
reinforcing
stability.
overlapping
confidence
intervals
batches
further
confirmed
that
no
statistically
significant
deviations
existed,
ensuring
batch-to-batch
variability,
validating
scalability
robustness
fermentation
These
findings
provide
strong
evidence
feasibility
meets
industrial
standards.
freeze-dried
product
retained
81%
viability
post-exposure
simulated
gastrointestinal
conditions,
meeting
WHO
establish
scalable,
optimized
production,
potential
applications
biopharmaceutical
manufacturing
food
development,
by
techno-economic
evaluations
performed
using
SuperPro
Designer®.
Antibiotics,
Год журнала:
2025,
Номер
14(4), С. 371 - 371
Опубликована: Апрель 3, 2025
The
human
gut
microbiota—an
intricate
and
dynamic
ecosystem—plays
a
pivotal
role
in
metabolic
regulation,
immune
modulation,
the
maintenance
of
intestinal
barrier
integrity.
Although
antibiotic
therapy
is
indispensable
for
managing
bacterial
infections,
it
profoundly
disrupts
microbial
communities.
Such
dysbiosis
typified
by
diminished
diversity
shifts
community
structure,
especially
among
beneficial
genera
(e.g.,
Bifidobacterium
Eubacterium),
fosters
antibiotic-resistant
strains
horizontal
transfer
resistance
genes.
These
alterations
compromise
colonization
resistance,
increase
permeability,
amplify
susceptibility
to
opportunistic
pathogens
like
Clostridioides
difficile.
Beyond
gastrointestinal
disorders,
emerging
evidence
associates
with
systemic
conditions,
including
chronic
inflammation,
syndrome,
neurodegenerative
diseases,
underscoring
relevance
microbiota–gut–brain
axis.
recovery
pre-existing
communities
post-antibiotic
highly
variable,
influenced
drug
spectrum,
dosage,
treatment
duration.
Innovative
interventions—such
as
fecal
microbiota
transplantation
(FMT),
probiotics,
synbiotics,
precision
microbiome
therapeutics—have
shown
promise
counteracting
mitigating
its
adverse
effects.
therapies
align
closely
stewardship
programs
aimed
at
minimizing
unnecessary
use
preserve
curtail
spread
multidrug-resistant
organisms.
This
review
emphasizes
pressing
need
microbiota-centered
strategies
optimize
administration,
promote
long-term
health
resilience,
alleviate
disease
burden
associated
antibiotic-induced
dysbiosis.
